EVO News and Press, Evotec SE From 06/13/25

2025-06-13 13:45:12 ET Investment Thesis I grant AbCellera Biologics Inc. ( ABCL ) a Hold rating. In my opinion, the critical aspect of the company is whether it will have sufficient financial resources until at least one of its agreements with other firms, or its drug devel...

Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations. The collaboration continues a successful partnership on evaluating new treatment regimens aimed at reducing treatment duration and overc...

2025-05-06 11:15:23 ET Evotec SE (EVO) Q1 2025 Earnings Conference Call May 6, 2025, 8:00 AM ET Company Participants Volker Braun - Head, Investor Relations Christian Wojczewski - Chief Executive Officer Paul Hitchin - Chief Financial Officer Conference Cal...

2025-05-06 08:32:24 ET More on Evotec SE Evotec SE (EVO) Q4 2024 Earnings Call Transcript Evotec SE 2024 Q4 - Results - Earnings Call Presentation Evotec SE reports Q4 results; initiates outlook for FY25 and FY28 Seeking Alpha’s Quant Rating on Evotec ...

Cyclerion Therapeutics Inc. (CYCN) is expected to report for Q1 2025 Standard BioTools Inc. (LAB) is expected to report $-0.06 for Q1 2025 Christian Dior SE ADR (CHDRY) is expected to report for Q1 2025 CF Bankshares Inc. (CFBK) is expected to report for Q1 2025 Jack Henry & A...

Group revenues of € 200 m, on track towards guidance; Shared R&D with similar trend as 2024; Just - Evotec Biologics with continuing growth momentum Strong progress in strategic protein degradation partnership with Bristol Myers Squibb Strategy building on technology and ...

HAMBURG, DE / ACCESS Newswire / April 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its interim statement for the first quarter of 2025 on Tuesday, 6 May 2025. The Company is going to hold a conference call to discuss the resu...

Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs Performance-based and program-based payments of in total US$ 75 m to Evotec HAMBURG, DE / ACCESS Newswire / April 24, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDA...

2025-04-17 14:24:50 ET Evotec SE (EVO) Q4 2024 Earnings Conference Call April 17, 2025 08:00 AM ET Company Participants Volker Braun - Head of Investor Relations Christian Wojczewski - Chief Executive Officer Paul Hitchin - Chief Financial Officer Cord Dohrma...

2025-04-17 03:40:47 ET More on Evotec SE Seeking Alpha’s Quant Rating on Evotec SE Historical earnings data for Evotec SE Financial information for Evotec SE Read the full article on Seeking Alpha For further details see: Evotec SE reports ...